Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis

Clinical Infectious Diseases

Volumn 59, Issue 8, 2014, Pages 1049-1063

  Cegielski, J Peter ^a   Dalton, Tracy ^a   Yagui, Martin ^b   Wattanaamornkiet, Wanpen ^c   Volchenkov, Grigory V ^d   Via, Laura E ^e   Van Der Walt, Martie ^f   Tupasi, Thelma ^g   Smith, Sarah E ^a   Odendaal, Ronel ^f   Leimane, Vaira ^h   Kvasnovsky, Charlotte ^a   Kuznetsova, Tatiana ^d   Kurbatova, Ekaterina ^a   Kummik, Tiina ⁱ   Kuksa, Liga ^h   Kliiman, Kai ⁱ   Kiryanova, Elena V ^j   Kim, Hee Jin ^k   Kim, Chang Ki ^k   Kazennyy, Boris Y ^j   Jou, Ruwen ^l   Huang, Wei Lun ^l   Ershova, Julia ^a   Erokhin, Vladislav V ^m   Diem, Lois ^a   Contreras, Carmen ⁿ   Cho, Sang Nae ^o,p   Chernousova, Larisa N ^m   Chen, Michael P ^a   Caoili, Janice Campos ^g   Bayona, Jaime ⁿ   Akksilp, Somsak ^c   more..

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c MINISTRY OF PUBLIC HEALTH   (Thailand)

^d Vladimir Oblast Tuberculosis Dispensary   (Russian Federation)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^g Tropical Disease Foundation   (Philippines)

^h RIGA EAST UNIVERSITY HOSPITAL   (Latvia)

ⁱ TARTU UNIVERSITY HOSPITAL   (Estonia)

^j Orel Oblast Tuberculosis Dispensary   (Russian Federation)

^k Korean Institute of Tuberculosis   (South Korea)

^l CENTER FOR DISEASE CONTROL   (Taiwan)

^m CENTRAL TUBERCULOSIS RESEARCH INSTITUTE   (Russian Federation)

ⁿ SOCIOS EN SALUD   (Peru)

^o International Tuberculosis Research Center   (South Korea)

^p Yonsei University College of Medicine   (South Korea)

more..

Author keywords

Extensively drug resistant tuberculosis; Green Light Committee; Multidrug resistant tuberculosis; Tuberculosis

Indexed keywords

AMIKACIN; CAPREOMYCIN; ETHAMBUTOL; ETHIONAMIDE; QUINOLONE DERIVATIVE; STREPTOMYCIN; THIOAMIDE; TUBERCULOSTATIC AGENT;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; COMORBIDITY; CONTROLLED STUDY; FEMALE; GENDER; GENOTYPE; GROUPS BY AGE; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG CAVITY; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; PROPENSITY SCORE; RISK FACTOR; SPUTUM CULTURE; TUBERCULOSIS CONTROL; ADOLESCENT; COHORT ANALYSIS; DRUG EFFECTS; GENETIC SELECTION; GENOTYPING TECHNIQUE; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PROSPECTIVE STUDY; SPUTUM; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; COHORT STUDIES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GENOTYPING TECHNIQUES; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PROSPECTIVE STUDIES; SELECTION, GENETIC; SPUTUM; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84921053905     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu572     Document Type: Article

References (24)

1. World Health Organization. The World Health Organization/ International Union Against Tuberculosis and Lung Disease Global Project on Anti-Tuberculosis Drug Resistance Surveillance: antituberculosis drug resistance in the world. Geneva, Switzerland: WHO, 1997.
2. World Health Organization. Basis for the development of an evidence-based case-management strategy for MDR TB within the WHO's DOTS Strategy. In: Proceedings of 1998 Meeting and Protocol Recommendations. Available at: http://www.who.int/tb/publications/1999/en/. Accessed 6 June 2014.
3. World Health Organization. WHO meeting to co-ordinate the DOTS-Plus workplan on pilot projects for the management of multidrug resistant (MDR) tuberculosis, 29 January 1999. Available at: http://www. who.int/tb/publications/1999/en/. Accessed 6 June 2014.
4. World Health Organization. DOTS-Plus and the Green Light Committee: improving access to second-line anti-TB drugs. Available at: http:// www.who.int/tb/publications/2000/en/. Accessed 6 June 2014.
5. World Health Organization. Global tuberculosis report 2012. Geneva, Switzerland: WHO, 2012.
6. World Health Organization Working Group on DOTS-Plus for MDR-TB. Procurement of second-line anti-tuberculosis drugs for DOTS-Plus pilot projects. Cambridge, MA, 5-6 July 1999. Available at: http://www. who.int/tb/publications/2000/en/. Accessed 20 March 2014.
7. World Health Organization. Guidelines for establishing DOTS-Plus pilot projects for the management of multidrug-resistant tuberculosis (MDR-TB). Geneva, Switzerland: WHO, 2000.
8. World Health Organization. Instructions for applying to the Green Light Committee for access to second-line anti-tuberculosis drugs. Geneva, Switzerland: WHO, 2002. Available at: http://www.who.int/tb/ publications/2001/en/. Accessed 27 March 2014.
9. Gupta R, Cegielski JP, Espinal MA, et al. Increasing transparency in partnerships for health-introducing the Green Light Committee. Trop Med Int Health 2002; 7:970-6.
10. Gupta R, Kim JY, Espinal MA, et al. Responding to market failures in tuberculosis control. Science 2001; 293:1049-51.
11. World Health Organization. GLC programmes applications. Available at: http://www.who.int/tb/challenges/mdr/greenlightcommittee/report- glc-applications-apr2011rev1.pdf Accessed 23 June 2011.
12. Dalton T, Cegielski P, Akksilp S, et al. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet 2012; 380:1406-17.
13. Clinical and Laboratory Standards Institute. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard. 2nd ed. CLSI document M24-A2. Wayne, PA: CLSI, 2011.
14. Kent PT, Kubica GP. Public health mycobacteriology a guide for the level III laboratory. Atlanta, GA: US Department of Health and Human Services, Public Health Service, Centers for Disease Control, 1985.
15. Cowan LS, Mosher L, Diem L, Massey JP, Crawford JT. Variable-number tandem repeat typing of Mycobacterium tuberculosis isolates with low copy numbers of IS6110 by using mycobacterial interspersed repetitive units. J Clin Microbiol 2002; 40:1592-602.
16. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984; 79:516-24.
17. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70:41-55.
18. Brookhart MA, Schneeweis S, Rothman KJ, Glynn RJ, Avorn J, Sturmer T. Variable selection for propensity score models. Am J Epi 2006; 163:1149-56.
19. Williamson E, Morley R, Lucas A, Carpenter J. Propensity scores: from naive enthusiasm to intuitive understanding. Stat Methods Med Research 2011; 21:273-93.
20. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011; 46:399-424.
21. World Health Organization. TB diagnostics and laboratory strengthening. Available at: http://who.int/tb/laboratory/mtbrifrollout/en/. Accessed 15 July 2013.
22. World Health Organization. Interim guidance on the use of bedaquiline to treat MDR-TB. Available at: http://www.who.int/tb/challenges/mdr/ bedaquiline/en/index.html. Accessed 15 July 2013.
23. Food and Drug Administration. FDA news release. Available at: http:// www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333.695.htm. Accessed 15 July 2013.
24. World Health Organization. Largest ever roll-out of GeneXpert(R) TB test machines, in 21 countries. Available at: http://www.who.int/tb/ features-archive/xpertprojectlaunch/en/. Accessed 21 March 2014.